CRISPR Therapeutics grants CTO 90,000 stock options

The awards have separate vesting schedules: the options begin vesting in 2027, while the units vest in four annual installments through 2030.

Available on EDGAR 11/06/2026 - 05:35 PM EST Accepted by SEC EDGAR 11/06/2026 - 05:35 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

CRISPR Therapeutics AG (CRSP) Chief Technical Officer Sivakesava Sakhamuri received two equity awards on November 4, 2026: options covering 90,000 common shares, with an exercise price of $51.78 per share, and 40,000 restricted stock units, each a contingent right to one common share. Twenty-five percent of the option shares vest on November 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter. The units vest in four equal installments on November 2 of 2027, 2028, 2029 and 2030.

Insider Trade Summary

Grant/Award: 130,000 shares

Grant/Award 2 txns

Insider Sakhamuri Sivakesava

Role Chief Technical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	90,000	$0.00	$0.00
Grant/Award	Restricted Stock Units F2, F3	40,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 90,000 contracts (Direct); Restricted Stock Units — 40,000 contracts (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 90,000 contracts (Direct); Restricted Stock Units, 0 to 40,000 contracts (Direct)

Footnotes (3)

1. F1. This option was granted on November 4, 2026 with respect to 90,000 Common Shares. 25% of the shares shall vest on November 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.
2. F2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
3. F3. This restricted stock unit award was granted on November 4, 2026 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on November 2, 2027, (ii) one quarter of the shares vesting on November 2, 2028, (iii) one quarter of the shares vesting on November 2, 2029, and (iv) one quarter of the shares vesting on November 2, 2030.

Key Figures

Stock options: 90,000 options covering Common Shares Option exercise price: $51.78 per share Restricted stock units: 40,000 units +1 more

4 metrics

Stock options 90,000 options covering Common Shares Granted November 4, 2026

Option exercise price $51.78 per share Options granted November 4, 2026

Restricted stock units 40,000 units Granted November 4, 2026

Option expiration November 4, 2036 Expiration date for the options

Key Terms

Stock Option (Right to Buy), Restricted Stock Units, contingent right, vest

4 terms

Stock Option (Right to Buy) financial

"This option was granted on November 4, 2026"

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"a contingent right to receive one share"

vest financial

"25% of the shares shall vest on November 2, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did CRSP's chief technical officer receive?

Sivakesava Sakhamuri received options covering 90,000 common shares at an exercise price of $51.78 per share, along with 40,000 restricted stock units. Each unit represents a contingent right to receive one common share.

When do CRSP's option and restricted stock unit awards vest?

Twenty-five percent of the option shares vest on November 2, 2027, and the remaining shares vest in 36 equal monthly installments thereafter. One quarter of the restricted stock units vest on each of November 2, 2027, 2028, 2029 and 2030.

When do CRSP's options expire?

The options expire on November 4, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sakhamuri Sivakesava

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MASSACHUSETTS 02127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$51.78	11/04/2026		A		90,000		(1)	11/04/2036	Common Shares	90,000	$0	90,000	D
Restricted Stock Units	(2)	11/04/2026		A		40,000		(3)	(3)	Common Shares	40,000	$0	40,000	D

Explanation of Responses:

1. This option was granted on November 4, 2026 with respect to 90,000 Common Shares. 25% of the shares shall vest on November 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.

2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

3. This restricted stock unit award was granted on November 4, 2026 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on November 2, 2027, (ii) one quarter of the shares vesting on November 2, 2028, (iii) one quarter of the shares vesting on November 2, 2029, and (iv) one quarter of the shares vesting on November 2, 2030.

	/s/ Elizabeth Ryland Waldinger, attorney-in-fact	11/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)